We are live on ! Find out more
PGEN icon

Precigen

137 hedge funds and large institutions have $85.6M invested in Precigen in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 45 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more call options, than puts

Call options by funds: $85K | Put options by funds: $17K

1.94% more ownership

Funds ownership: 23.72%25.65% (+1.9%)

1% less capital invested

Capital invested by funds: $86M → $85.6M (-$450K)

1% less funds holding

Funds holding: 138137 (-1)

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

24% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 45

Holders
137
Holders Change
-1
Holders Change %
-0.72%
% of All Funds
2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
34
Reduced
45
Closed
19
Calls
$85K
Puts
$17K
Net Calls
+$68K
Net Calls Change
-$75K

PGEN Hedge Fund Activity: Q4 2023 in Review

137 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Precigen (PGEN) for Q4 2023, worth a combined $85.6M — down 0.52% from $86M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PGEN and 18 opened new positions — a net loss of 1 holder — while 45 trimmed existing stakes and 34 added.

The largest buyer was Patient Capital Management, adding an estimated $2.62M. The largest seller was GMT Capital, exiting entirely with an estimated $950K sold.

  • 137 institutional investors held Precigen (PGEN) as of Q4 2023, down from 138 in Q3 2023.
  • Funds reported $85.6M of Precigen stock for Q4 2023, down 0.52% quarter-over-quarter.
  • 18 funds opened new Precigen positions in Q4 2023 and 19 closed out, a net change of -1 holder.
  • The largest Precigen buyer in Q4 2023 was Patient Capital Management, an estimated $2.62M added.
  • The largest Precigen seller in Q4 2023 was GMT Capital, an estimated $950K sold.

Based on aggregated 13F filings for Q4 2023.